Opticon to merge with Immune Response Inc:
This article was originally published in Clinica
Opticon Medical, a privately owned development stage company, is to be acquired by Immune Response Inc of Englewood Colorado, in a deal which will give Opticon an OTC listing. Immune ends up with 20% of the equity of the merged company. Opticon, based in Dublin, Ohio, is developing the OPTICON, a proprietary, silicone, disposable, valved urinary tract catheter which does not require a system of collection tubes or bags. Immune has no connection with the Californian company, Immune Response Corporation.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.